The combination of p53 mutations and Ras pathway alterations in angiosarcoma was modeled in recent independent studies, and these tumors may be sensitive to mTOR or Ras pathway inhibition [6,7,8,9]. The gene discussed is TP53; the disease is angiosarcoma.